About US
Contact us
-
FDA approves Pfizer’s Daurismo to treat acute myeloid leukaemiaThe US Food and Drug Administration (FDA) has approved Pfizer’s Daurismo (glasdegib) indication to treat patients with newly diagnosed acute myeloid leukaemia (AML). The once-daily oral medicine is t2018/11/26
-
EU approves Camurus’s Buvidal injections to treat opoid dependencySwedish research-based pharmaceutical and biotechnology company Camurus has received European Commission (EC) approval for weekly and monthly Buvidal injections to treat opioid dependency in adults an2018/11/26
-
Moments matter in Pfizer and Bristol-Myers Squibb's latest pitch for afib awarenessPfizer and Bristol-Myers Squibb are taking on atrial fibrillationagain with a newawareness campaign. Called “Matter of Moments,” the multichannel effort looks to raise awareness about the connection b2018/11/23
-
Mylan West Virginia plant tagged with warning letter by FDAThe other shoe has finally dropped on Mylan’s troubled manufacturing plant in West Virginia. The drugmaker acknowledged Tuesday that the FDA this month issued a warning letter for the problems at the2018/11/23
-
Takeda gets conditional EC approval for $62bn Shire acquisitionTakeda Pharmaceutical has received a conditional approval from the European Commission (EC) for the $62bn proposed acquisition of Irish biopharmaceutical company Shire. The EC clearance is conditiona2018/11/22
-
Sobi’s Gamifant obtains FDA approval to treat Primary HLHSobi and Novimmune have secured approval from the US Food and Drug Administration (FDA) for Gamifant (emapalumab-lzsg), the first and only treatment indicated for Primary Hemophagocytic Lymphohistiocy2018/11/22
-
Alvotech teams with Fuji Pharma for biosimilar portfolio in JapanIceland-based Alvotech has signed a deal for commercialisation of its biosimilar portfolio in Japan in an exclusive partnership agreement with Fuji Pharma. Under the partnership, Alvotech will develo2018/11/21
-
Merck and Palantir to form JV to advance cancer researchMerck has signed a non-binding term sheet to establish a joint venture (JV) with data analytics firm Palantir Technologies to support the advancement of cancer research. The JV will be known as Syntr2018/11/21
-
Pfizer, Merck KGaA's Bavencio flunks another trial, this time in ovarian cancerMark another tally for Pfizer and Merck KGaA’s Bavencio in the “loss” column. Monday, the drugmakersreportedthat their immuno-oncology drug had failed a phase 3 trial in previously treated ovarian ca2018/11/20
-
Eli Lilly weighs $200M-plus sale of declining China drug portfolio: reportThe news comes amid a long turnaround effort that’s just now starting to bear fruit. Lilly has launched 10 new drugs since 2014, not just in diabetes but also in high-growth markets such as cancer a2018/11/20